GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2007

Ardea Receives $0.5M from Valeant upon Selection of Development Candidates

  • Ardea Biosciences received its first milestone payment of $0.5 million from Valeant Pharmaceuticals. The fee was triggered by Valeant's selection of several pre-IND candidates for its potassium-channel opener program.

    In December 2006, Ardea bought certain discovery and preclinical assets from Valeant. Separately, Valeant also signed a deal to pay Ardea for research on unidentified neurological treatments.

    "Starting with a very interesting first-generation compound, we have successfully improved its metabolic and pharmacokinetic properties, while increasing potency by up to 50-fold,” says Barry D. Quart,  president and CEO of Ardea. “We are pleased to be recognized for achieving this important milestone and for its validation of our fully-integrated discovery, research, and development platform.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?